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Homocysteine — differing
conclusions
From a funding perspective we are told that there is an
increasing demand to spend money on pharmacological
vascular risk reduction. Guidelines for hypertension,
dyslipidaemia and type 2 diabetes are therefore advocating
ever-decreasing optimal target levels for blood pressure, lipid
and glucose control, which commonly require combination
therapy rather than monotherapy. The list of medicines to
reduce long-term vascular morbidity and mortality is growing
and the advocated doses of such drugs are increasing. Such
medication can be very expensive, and there are also associated
costs: for example, the BHF rates for homocysteine tests are
R87.70 (random) and R103.70 after methionine loading. Should
we test for plasma homocysteine, and what is the evidence for
intervention when the levels are raised? Two reviews in this
issue illustrate the folly of relying on reports, which may be
biased in favour of intervention without adequate proof.
Jacobs and Wood (p. 191) review the pathophysiology of
homocysteine and the vascular endothelium and find it
inexplicable that controversy persists regarding treatment.
They speculate that ‘perhaps this is because, for primary
prevention, proof of benefit is not yet sufficient to justify
worldwide supplementation although preliminary results are
expected to reach statistical significance within 3 years’.
Despite the uncertain evidence the authors go on to state
‘rationally it is recognised that local authority or government
need to add at least folate to some widely consumed food
staple’. They conclude that the argument is compelling and
‘needs to be widely acknowledged and responded to by
doctors and nurses as well as third party payers in South
Africa — as it is elsewhere in the world’.
The review by Mbewu, Nogoduka and Taylor (p. 192)
examines both sides of the argument of plasma homocysteine
and arterial thromboembolic disease and comes to conclusions
that differ from the above. The traditional risk factors for
coronary heart disease (CHD) — cigarette smoking,
hypertension, diabetes mellitus, age, raised total cholesterol,
low high-density lipoprotein — may be insufficient to account
for all cases of CHD. Novel risk factors such as homocysteine
have therefore gained popularity as potential independent risk
factors for CHD. High serum homocysteine concentrations are
associated inter alia with genetically determined enzyme
dysfunction, methionine-rich diets, excessive coffee
consumption, high alcohol intake, smoking and lack of
physical activity. Although homocysteine appears to be
positively associated with vascular events, it remains to be seen
whether it is an independent, and furthermore causal risk
factor for thromboembolic disease. No results of prospective
randomised trials are as yet available to establish the effects on
cardiovascular outcomes of lowering homocysteine, or to
ascertain the effect of folate and vitamin B6 supplementation on
such events. It is therefore premature to advocate screening
and intervention programmes for elevated homocysteine
levels.
Most importantly, the health benefits of prudent living and
eating, rather than relying on hopeful enthusiasm for yet
another pill, are reinforced!
Does calcium supplementation
prevent pre-eclampsia?
Public health interventions such as vaccination against
infectious diseases and the fluoridation of drinking water have
strongly beneficial effects, particularly in poorer communities.
Does calcium supplementation in an attempt to prevent pre-
eclampsia fall into this category?
High blood pressure with or without proteinuria is a major
cause of both maternal and perinatal death and morbidity
worldwide. Preterm birth, commonly associated with
hypertensive disorders, is the leading cause of early neonatal
death and infant mortality, particularly in low-income
countries. For these reasons, strategies to reduce the risk of
hypertensive disorders of pregnancy have received
considerable attention. Hofmeyr et al. (p. 224) therefore
undertook a systematic review of randomised trials that
compared supplementation with at least 1 g calcium daily
during pregnancy with placebo.
They found that there was a modest reduction of risk of pre-
eclampsia with calcium supplementation. The effect was
greatest for women at high risk of hypertension and those with
low baseline calcium intake. Since these benefits were confined
to several small trials and not found in the largest trial
conducted in a low-risk population, further research is
required.
Rheumatic fever — a jab is
better than a swallow
Rheumatic fever (RF) is the most important cause of acquired
heart disease in children and young adults worldwide. The
prevalence of RF and rheumatic heart disease is high in areas
with poor socioeconomic conditions, overcrowding and limited
access to medical care. The severity and prognosis of rheumatic
heart disease depend on the extent of the carditis and the
frequency of recurrent attacks. Secondary prevention is
particularly important since even an asymptomatic or
optimally treated group A streptococcal throat infection can
still trigger RF recurrence.
Manyemba and Mayosi (p. 212) provide a systematic review
assessing the effects of different penicillin regimens and
formulations for preventing streptococcal infection and RF
recurrence. They conclude that intramuscular penicillin is more
effective than oral penicillin in preventing RF recurrence and
streptococcal throat infections. Two-weekly or 3-weekly
injections appeared to be more effective than 4-weekly
injections. They caution that the evidence is based on poor-
quality trials and the use of outdated formulations of penicillin.
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